$19.700
-0.686 (-3.48%)收盘时
SDGR 资讯
SDGR 事件
Schrodinger Provides Financial Guidance for FY 2026
As of August 5, 2026, Schrodinger provided the following financial guidance for the fiscal year ending December 31, 2026: ACV is expected to range from $21M-$228M, representing 10-15% growth over 2025. Drug discovery revenue is expected to range from $65 million to $75 million, compared to the prior expectation of $55M-$65 M, due to the achievement of a $10M collaboration milestone associated with the Ajax acquisition. Operating expenses are expected to be less than 2025
Schrodinger Reports Q2 Revenue of $58.889M, Beating Expectations
Reports Q2 revenue $58.889M, consensus $47.24M. "We are very pleased with our second quarter results, delivering ACV of $29.6 million, which represents 27% growth. Our results reflect growing industry adoption of a predict-first approach to molecular discovery," said Ramy Farid, Ph.D., chief executive officer of Schrodinger. "As biopharma navigates a rapidly evolving AI landscape and mounting pressure to optimize and accelerate the discovery of new medicines, the need to generate ground-truth data has never been greater. By integrating our highly accurate, physics-based simulations with AI, and launching our agentic co-scientist Bunsen, we are enabling teams to execute complex workflows on a large scale and building the definitive computational infrastructure for the future of drug discovery."
Schrodinger Announces Strategic Agreement with Bristol Myers Squibb
Schrodinger (SDGR) announced a strategic agreement with Bristol Myers Squibb (BMY) to deploy Bunsen, Schrodinger's agentic AI co-scientist, within its research organization. The new agreement significantly expands the application of Schrodinger's platform, empowering BMS scientists to explore more scientific possibilities, prioritize molecules with greater confidence, and accelerate discovery decisions. Under the agreement, Schrodinger will collaborate with BMS scientists on developing novel functionality within Bunsen in conjunction with its computational technologies designed to enable large-scale chemical exploration as well as with RetroSynth, its AI-driven synthesis planning platform. "BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery. We are thrilled they are deploying Bunsen at a large scale," said Robert Abel, Chief Scientific Officer, Platform, of Schrodinger. "Adopting Bunsen and our computational platform at scale will empower a broader group of scientists to embrace a predict-first computational approach."
Schrodinger Launches Early Access Version of AI Co-Scientist Bunsen
Schrodinger (SDGR) announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies, execute sophisticated molecular discovery workflows and interpret results. The company said, "By combining AI with physics-based simulation, Bunsen allows researchers to apply their expertise at greater scale, enabling them to explore more scientific possibilities, prioritize the most promising opportunities with greater confidence and accelerate discovery decisions. Advances in computer-aided drug discovery have expanded what researchers can model and simulate, but the complexity of designing, executing and interpreting those studies has grown alongside it. Built for molecular discovery, Bunsen was designed specifically to address that challenge. Unlike general-purpose AI systems that only retrieve and summarize existing scientific information, Bunsen is optimized to execute Schrodinger's validated computational methods and leverages decades of the company's physics-based molecular discovery expertise. With Bunsen, researchers can now evaluate more hypotheses, explore chemical space more efficiently and make higher-confidence decisions before compounds move into experimental testing. This helps computational chemists run concurrent research sessions and accomplish more across multiple programs. At the same time, Bunsen makes advanced computational methods accessible to experienced drug hunters who are not computational chemists." As part of Schrodinger's collaborations with NVIDIA (NVDA) and Google Cloud (GOOG), both companies will provide a co-engineered full stack AI platform to support early Bunsen customers, helping research organizations scale their use of the platform across discovery programs. The collaboration also includes Google Cloud's elastic computing infrastructure and the ability to integrate Schrodinger's platform with the NVIDIA BioNeMo Agent Toolkit and the NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs.
Schrodinger Grants 3,691 Restricted Stock Units to Four New Employees
Schrodinger reported that on July 16, the company granted restricted stock units with respect to 3,691 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。